YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
Autonomix Medical, Inc. Autonomix Medical, Inc.Autonomix Medical Appoints Former Medtronic Chief Regulatory Counsel Sandra Cohen Kalter to Board of Directors Appointment adds more than four decades of MedTech leadership, FDA regulatory and…
* Autonomix Medical (AMIX [https://seekingalpha.com/symbol/AMIX]) entered [https://seekingalpha.com/pr/20628447-autonomix-medical-enters-into-4_9-million-warrant-inducement-priced-at-a-premium-to-market] into a warrant inducement agreement…
Recognition honors one of the medical technology industry's most influential innovators, whose career has helped shape modern cardiovascular care THE WOODLANDS, TX, Aug. 10, 2026 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (…
(RTTNews) - Autonomix Medical Inc. (AMIX) announced the issuance of U.S. Patent No. 12,433,670 covering systems designed to sense, map, and selectively target nerves associated with tumors, cancer-related pain, and autonomic nervous system…
(RTTNews) - Today's top biotech gainers include SciSparc, after its subsidiary successfully completed internal validation of a proprietary quantum sampling platform designed to analyze clinical trial data; Avantor, following the release of…
(RTTNews) - Autonomix Medical Inc. (AMIX), a medical device company, on Friday announced preclinical results of a neural sensing platform to facilitate renal denervation and identify changes in renal neural activity. Renal denervation has…
Patent Broadens Intellectual Property Protecting Advanced Autonomic Nervous System Assessment Technologies Designed to Enhance Patient Selection, Treatment Precision and Future Clinical Applications THE WOODLANDS, TX, July 23, 2026 (GLOBE…
(RTTNews) - Autonomix Medical, Inc. (AMIX), a medical device company, announced that the U.S. Patent and Trademark Office (USPTO) has granted U.S. Patent No. 12,611,134 covering its platform for the diagnosis and treatment of overactive bl…
* Autonomix Medical (AMIX [https://seekingalpha.com/symbol/AMIX]) entered into a warrant inducement agreement with an existing investor that is expected to generate about $2.6M in gross proceed [https://seekingalpha.com/pr/20581077-autonom…
THE WOODLANDS, TX, July 13, 2026 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerve-targeted treatments, today announced it has entered…
(RTTNews) - Autonomix Medical, Inc. (AMIX) has filed an amendment to its certificate of incorporation to effect a 1-for-21 reverse stock split of its common stock. The split will take effect on June 24, 2026, with shares opening for tradin…
Autonomix Medical, Inc. THE WOODLANDS, TX, June 18, 2026 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) ("Autonomix" or the "Company"), a medical device company dedicated to advancing precision nerve-targeted treatments, today…
Technology unlocks minimally invasive transvascular access to nerve targets and tissues through and beyond the lumen wall Patent strengthens intellectual property foundation for next-generation neuromodulation technologies THE WOODLANDS, T…
THE WOODLANDS, TX, March 04, 2026 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerve-targeted treatments, today announced that Nikola C…
NEW YORK (AP) — prices for the Nasdaq composite, NYSE and NYSE American listed most active stocks. Nasdaq most active stocks: Stock Name Volume High Low Last Change Profusa Inc. 531,709,308 0.1695 0.1309 0.132 +0.0637 Autonomix Medical, In…
THE WOODLANDS, TX, Nov. 26, 2025 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerve-targeted treatments, today announced the next CEO C…
* Autonomix Medical (NASDAQ:AMIX [https://seekingalpha.com/symbol/AMIX]) stated [https://seekingalpha.com/pr/20311453-autonomix-medical-inc-announces-pricing-of-5_0-million-private-placement-priced-at-the-market] on Tuesday that it has ent…
NEW YORK (AP) — prices for the Nasdaq composite, NYSE and NYSE American listed most active stocks. Nasdaq most active stocks: Stock Name Volume High Low Last Change UTime Ltd. 671,702,035 0.0353 0.0266 0.0275 +0.0036 Autonomix Medical, Inc…
THE WOODLANDS, TX, Oct. 24, 2025 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerve-targeted treatments, today announced it will be fea…
THE WOODLANDS, TX, Oct. 16, 2025 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerve-targeted treatments, today announced it will partic…
Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Re…
With over 120 issued and pending patent applications, Autonomix is building a comprehensive, global IP portfolio in nerve-sensing and modulation Newly issued patent strengthens the Company’s strategic position in a multi-billion-dollar mar…
THE WOODLANDS, TX, Oct. 02, 2025 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerve-targeted treatments, today announced the next CEO C…
GLP study marks a key milestone in Autonomix's path to achieve regulatory approvals Company remains on track to submit Investigational Device Exemption (“IDE”), and if approved, commence U.S. clinical trials in 2026 to support a De Novo FD…
* Autonomix Medical (NASDAQ:AMIX [https://seekingalpha.com/symbol/AMIX]) has filed a prospectus to allow resale of up to 2.5M shares of common stock by Lincoln Park Capital Fund. * Includes 2.24M purchase shares that may be issued to Linco…
Dr. Robert Schwartz, Chief Medical Officer of Autonomix, discusses the Company’s recently announced results from the post hoc analysis of its proof-of-concept human clinical trial (“PoC 1”) THE WOODLANDS, TX, Sept. 04, 2025 (GLOBE NEWSWIRE…
After the conclusion of the US market's regular session on Tuesday, let's examine the after-hours session and unveil the notable performers among the top gainers and losers. [postmarket] TODAY'S AFTER HOURS GAINERS TICKER CHANGE COMMENT ST…
THE WOODLANDS, TX, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the…
Live video webcast on Thursday, August 21st at 1:00 PM ET Register here THE WOODLANDS, TX, Aug. 18, 2025 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company focused on advanci…
– Live video webcast on Thursday, August 21st at 2:20 PM ET THE WOODLANDS, TX, Aug. 15, 2025 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company focused on advancing precision…
Microchip-based platform enables real-time nerve mapping and targeted treatment from within the vascular system Continued progress toward submitting Investigational Device Exemption (“IDE”), and if approved, the commencement of U.S. clinic…
– Video webcast now available on-demand THE WOODLANDS, TX, July 22, 2025 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company focused on advancing innovative technologies to re…
THE WOODLANDS, TX, July 22, 2025 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerve-targeted treatments, today announced it has entered…
With over 80 issued patents and 40 pending patent applications, Autonomix is building a comprehensive IP portfolio in nerve-sensing and modulation, strengthening its strategic position in a multi-billion-dollar market opportunity and unloc…
THE WOODLANDS, TX, July 07, 2025 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerve-targeted treatments, today announced the next CEO C…
Expansion of study into additional indications doubles the potential addressable market beyond pancreatic cancer pain PoC 2 phase builds on early success and positive results demonstrated in PoC 1 in patients with severe pancreatic cancer…